Claims for Patent: 5,545,403
✉ Email this page to a colleague
Summary for Patent: 5,545,403
Title: | Method for treating a mammal by administering a CHO-glycosylated antibody |
Abstract: | The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation. |
Inventor(s): | Page; Martin J. (Beckenham, GB) |
Assignee: | Burroughs Wellcome Co. (Research Triangle Park, NC) |
Application Number: | 08/155,864 |
Patent Claims: | 1. In a method for treating a human suffering from a disease or disorder comprising administering a therapeutically effective amount of a whole glycosylated recombinant human chimeric
or CDR-grafted or bispecific antibody effective in treating said disease or disorder in said human, wherein the improvement comprises an antibody glycosylated by a chinese hamster ovary cell.
2. The method of claim 1, wherein said antibody specifically binds CD4. 3. The method of claim 1, wherein said antibody specifically binds CDw52. 4. The method of claim 2, wherein said antibody is a CDR-grafted antibody. 5. The method of claim 3, wherein said antibody is a CDR-grafted antibody. 6. The method of claim 2, wherein said antibody is a chimeric antibody. 7. The method of claim 3, wherein said antibody is a chimeric antibody. |
Details for Patent 5,545,403
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | May 07, 2001 | ⤷ Sign Up | 2013-08-13 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | November 14, 2014 | ⤷ Sign Up | 2013-08-13 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | October 12, 2004 | ⤷ Sign Up | 2013-08-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,545,403
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 918248 | ⤷ Sign Up |
United States of America | 5545405 | ⤷ Sign Up |
United States of America | 5545404 | ⤷ Sign Up |
United States of America | 2008279852 | ⤷ Sign Up |
United States of America | 2004228857 | ⤷ Sign Up |
United States of America | 2003035799 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.